Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance

Vincent L Chen¹, Timothy R Morgan^{2

3}, Yaron Rotman⁴, Heather M Patton^{5

6}, Kenneth Cusi⁷, Fasiha Kanwal^{8

9

10}, W Ray Kim¹¹

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
² Division of Gastroenterology, University of California Irvine, Irvine, CA, USA.
³ VA Long Beach Healthcare System, Long Beach, CA, USA.
⁴ Liver and Energy Metabolism Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
⁵ Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, USA.
⁶ VA San Diego Healthcare System, San Diego, CA, USA.
⁷ Division of Endocrinology, Diabetes, and Metabolism, University of Florida, Gainesville, FL, USA.
⁸ Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
⁹ VA Health Services Research and Development Service, Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX, USA.
¹⁰ Michael E. DeBakey VA Medical Center, Houston, TX, USA.
¹¹ Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Vincent L Chen et al. Hepatology. 2025.

. 2025 Jan 1;81(1):312-320.

doi: 10.1097/HEP.0000000000001112. Epub 2024 Oct 18.

Vincent L Chen¹, Timothy R Morgan^{2

3}, Yaron Rotman⁴, Heather M Patton^{5

6}, Kenneth Cusi⁷, Fasiha Kanwal^{8

9

10}, W Ray Kim¹¹

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
² Division of Gastroenterology, University of California Irvine, Irvine, CA, USA.
³ VA Long Beach Healthcare System, Long Beach, CA, USA.
⁴ Liver and Energy Metabolism Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
⁵ Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, USA.
⁶ VA San Diego Healthcare System, San Diego, CA, USA.
⁷ Division of Endocrinology, Diabetes, and Metabolism, University of Florida, Gainesville, FL, USA.
⁸ Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
⁹ VA Health Services Research and Development Service, Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX, USA.
¹⁰ Michael E. DeBakey VA Medical Center, Houston, TX, USA.
¹¹ Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Erratum in

Erratum: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.
Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, Kim WR. Chen VL, et al. Hepatology. 2025 Apr 1;81(4):E133. doi: 10.1097/HEP.0000000000001186. Epub 2025 Feb 12. Hepatology. 2025. PMID: 39937959 No abstract available.

No abstract available

1. Rezdiffra. Prescribing information. Madrigal Pharmaceuticals; 2024. Accessed June 17, 2024. https://www.madrigalpharma.com/wp-content/uploads/2024/06/NDA-217785_REZ... .
1. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497–509.
1. Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29:2919–2928.
1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835.
1. Sterling RK, Duarte-Rojo A, Patel K, Asrani SK, Alsawas M, Dranoff JA, et al. AASLD practice guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843. - DOI